This site is intended for healthcare professionals only
LoginRegister
Centre nod to Bharat Biotech nasal COVID vaccine iNCOVACC, to be availabile in private hospitalsCentre nod to Bharat Biotech nasal COVID vaccine iNCOVACC, to be availabile in private hospitals
SEC Approves Serums Salk Polio Vaccine for Commercial Use, Recommends Phase I Trial for 21-valent Pneumococcal VaccineCOVID vaccine: SII seeks DCGI nod for market authorisation of Covovax as booster dose
Bivalent mRNA booster vaccine reduces risk of severe COVID-19 by more than half: CDCBivalent mRNA booster vaccine reduces risk of severe COVID-19 by more than half: CDC
European Commission approves Qdenga as second dengue virus vaccineEuropean Commission approves Qdenga as second dengue virus vaccine
New Tomato flu variant creates health scare among kids in several statesNew Tomato flu variant creates health scare among kids in several states
S pneumoniae infection treatment: DCGI nod to Biological E 14-valent paediatric Pneumococcal Conjugate VaccineS pneumoniae infection treatment: DCGI nod to Biological E 14-valent paediatric Pneumococcal...
COVID-19 vaccination more protective against death and hospitalization compared to natural immunityCOVID-19 vaccination more protective against death and hospitalization compared to natural immunity
Bharat Serums and Vaccines to buy Firstline Pharma, Genomicks to expand presence in womens health in MalaysiaBharat Serums and Vaccines to buy Firstline Pharma, Genomicks to expand presence in women's health...
Antiviral drug nirmatrelvir plus ritonavir effective in reducing COVID-19 hospitalization among vaccinated adults 50 and overAntiviral drug nirmatrelvir plus ritonavir effective in reducing COVID-19 hospitalization among...
SII Cervical cancer vaccine CERVAVAC likely to be launched in April next yearSII Cervical cancer vaccine CERVAVAC likely to be launched in April next year
Ebola vaccines safety and immunogenicity trial shows potentialEbola vaccines safety and immunogenicity trial shows potential
Pfizer eyes USD 10 billion- USD 15 billion in potential revenue from mRNA vaccines by 2030Pfizer eyes USD 10 billion- USD 15 billion in potential revenue from mRNA vaccines by 2030
X